Beta-Endorphin Binds to Kidney Membranes Through Both Opioid and Non-Opioid Mechanisms
Beta-endorphin binds to kidney membranes through two distinct sites — a high-affinity opioid receptor and a high-capacity non-opioid site — suggesting most kidney effects may bypass traditional opioid receptors.
Quick Facts
What This Study Found
Beta-endorphin binds to kidney membranes through both opioid (high-affinity, low-capacity) and non-opioid (low-affinity, high-capacity) sites. The non-opioid binding involves the mid-portion of the peptide.
Key Numbers
How They Did This
Radioiodinated beta-endorphin binding to rat renal basolateral membranes was characterized by saturation isotherms, competition with naloxone and other opioid peptides, and Scatchard analysis.
Why This Research Matters
Beta-endorphin affects kidney function, and most of this may work through non-opioid mechanisms. This is important for understanding how opioid drugs affect kidney function.
The Bigger Picture
The kidney is critical for fluid balance and blood pressure. Finding that beta-endorphin affects kidneys mainly through non-opioid mechanisms means that opioid-blocking drugs may not prevent all of opioid peptides' kidney effects — important for understanding opioid drug side effects on kidney function.
What This Study Doesn't Tell Us
In-vitro binding study. The functional consequences of non-opioid binding in the kidney were not tested. Only one species was examined.
Questions This Raises
- ?What kidney functions are regulated by the non-opioid beta-endorphin binding site?
- ?Are these non-opioid kidney effects clinically significant for patients on opioid therapy?
Trust & Context
- Key Stat:
- Non-opioid binding dominates The high-capacity non-opioid binding site on kidney membranes may mediate most of beta-endorphin's renal effects
- Evidence Grade:
- Preliminary in-vitro binding study in rat kidneys. Characterizes binding sites but does not test functional consequences.
- Study Age:
- Published in 1990. Non-opioid effects of beta-endorphin remain an active research area.
- Original Title:
- Specific binding of beta-endorphin to the isolated renal basolateral membranes in vitro.
- Published In:
- Chemical & pharmaceutical bulletin, 38(12), 3395-9 (1990)
- Authors:
- Sato, H(2), Takeda, K, Terasaki, T, Tsuji, A
- Database ID:
- RPEP-00166
Evidence Hierarchy
Frequently Asked Questions
What does non-opioid binding mean?
Beta-endorphin can stick to kidney cell membranes at sites that are not traditional opioid receptors. These sites recognize a different part of the peptide and are not blocked by opioid antagonists like naloxone.
Why does this matter for kidney function?
If most of beta-endorphin's kidney effects work through non-opioid sites, then opioid-blocking drugs won't prevent all kidney effects — important for managing patients on opioid therapy.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-00166APA
Sato, H; Takeda, K; Terasaki, T; Tsuji, A. (1990). Specific binding of beta-endorphin to the isolated renal basolateral membranes in vitro.. Chemical & pharmaceutical bulletin, 38(12), 3395-9.
MLA
Sato, H, et al. "Specific binding of beta-endorphin to the isolated renal basolateral membranes in vitro.." Chemical & pharmaceutical bulletin, 1990.
RethinkPeptides
RethinkPeptides Research Database. "Specific binding of beta-endorphin to the isolated renal bas..." RPEP-00166. Retrieved from https://rethinkpeptides.com/research/sato-1990-specific-binding-of-betaendorphin
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.